Novartis announces that its clinical trial of QMF1493, a compound-in-search powder mist, has reached its primary and secondary endpoints

today, Novartis announced that its compound inhalation powder mist agent QMF149, in the treatment of asthma patients in the phase 3 clinicaltrial(http://QUARTZ achieved positive results, reached the main and secondary ends of the trialon QMF149
As a daily fixed-dose, perinataldrug(http://, QMF149 consists of a long-acting beta-2 receptor agonist (LABA) indaol acetate (nidatero), and an inhalable corticosteroid (ICS)tasone furoa (momisin)In a randomized, double-blind, active-controlled Phase 3 clinical trial, QUARTZ, patients with inadequate asthma control were treated with low doses of QMF149 (150/160 ?g), or momissone (200 ?g) of the acidresults showed that after 12 weeks, the QMF149 low-dose group not only achieved a significant improvement in the patient's lung function, the main endpoint of the patient's lung function, increased the amount of 1 second strong exhalation (FEV1) by an average of 182 ml, but also increased the patient's nightly exhalation flow (evening PEF) by 26.1 liters per minute, which further showed that QMF149 improved clinical function in the lung sensein addition, at week 12, the QMF149 low-dose group showed a statistically significant improvement in asthma control (ACQ-7) compared to the control group, and a higher rate of remission (74.7 percent vs64.9 percent) reached the secondary endpoint of the trial